Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 6
2007 9
2008 17
2009 11
2010 11
2011 20
2012 35
2013 45
2014 45
2015 69
2016 65
2017 56
2018 41
2019 38
2020 56
2021 43
2022 37
2023 27
2024 16
2025 19
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

549 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flügel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Möllmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schühlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tölg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A; ISAR-REACT 5 Trial Investigators. Schüpke S, et al. N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Epub 2019 Sep 1. N Engl J Med. 2019. PMID: 31475799 Clinical Trial.
BACKGROUND: The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive evaluation is planned are uncertain. ...Definite or probable stent thrombosis occurred in 1.3% of patients assigned to ticagrelor and 1.0% o …
BACKGROUND: The relative merits of ticagrelor as compared with prasugrel in patients with acute coronary syndromes for whom invasive …
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Wiviott SD, et al. N Engl J Med. 2007 Nov 15;357(20):2001-15. doi: 10.1056/NEJMoa0706482. Epub 2007 Nov 4. N Engl J Med. 2007. PMID: 17982182 Free article. Clinical Trial.
RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant …
RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel …
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. Gimbel M, et al. Lancet. 2020 Apr 25;395(10233):1374-1381. doi: 10.1016/S0140-6736(20)30325-1. Lancet. 2020. PMID: 32334703 Clinical Trial.
BACKGROUND: Current guidelines recommend potent platelet inhibition with ticagrelor or prasugrel in patients after an acute coronary syndrome. However, data about optimal platelet inhibition in older patients are scarce. ...FINDINGS: Between June 10, 2013, and Oct 17, 2018 …
BACKGROUND: Current guidelines recommend potent platelet inhibition with ticagrelor or prasugrel in patients after an acute coronary …
Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
Ray A, Najmi A, Khandelwal G, Jhaj R, Sadasivam B. Ray A, et al. Cardiovasc Drugs Ther. 2021 Jun;35(3):561-574. doi: 10.1007/s10557-020-07056-z. Epub 2020 Aug 20. Cardiovasc Drugs Ther. 2021. PMID: 32816142
PURPOSE: Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor or prasugrel is the mainstay of treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). ...CONCLUSION: In patients with ACS undergoing PCI, both …
PURPOSE: Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor or prasugrel is the mainstay of treatment for patients with acu …
Reduced-Dose Prasugrel versus Clopidogrel for Patients Undergoing Percutaneous Coronary Intervention.
Lee CH, Huang MS, Chao TH, Lin SH, Li YH. Lee CH, et al. Int Heart J. 2021 Mar 30;62(2):246-255. doi: 10.1536/ihj.20-508. Epub 2021 Mar 17. Int Heart J. 2021. PMID: 33731521 Free article.
Whether reduced-dose prasugrel has a better efficacy or safety than standard-dose clopidogrel remains unknown in patients undergoing percutaneous coronary intervention (PCI).A systematic search of PubMed, EMBASE, Google Scholar, and Cochrane Library from database inception …
Whether reduced-dose prasugrel has a better efficacy or safety than standard-dose clopidogrel remains unknown in patients undergoing …
Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Shah RP, Shafiq A, Hamza M, Maniya MT, Duhan S, Keisham B, Patel B, Alamzaib SM, Yashi K, Uppal D, Sattar Y, Tiwari D, Paul TK, AlJaroudi W, Alraies MC. Shah RP, et al. Am J Cardiol. 2023 Nov 15;207:206-214. doi: 10.1016/j.amjcard.2023.08.117. Epub 2023 Sep 24. Am J Cardiol. 2023. PMID: 37751668
The overall mean age was 62.73 years, whereas the mean age for the ticagrelor and prasugrel groups was 63.80 and 61.65 years, respectively. Prasugrel is equally effective as compared with ticagrelor in preventing MI. ...In patients with acute coronary syndrome, p …
The overall mean age was 62.73 years, whereas the mean age for the ticagrelor and prasugrel groups was 63.80 and 61.65 years, respect …
Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z, Zhou DY, Su Y, Si LY, Xu Q. Wang Z, et al. BMC Cardiovasc Disord. 2020 Mar 12;20(1):130. doi: 10.1186/s12872-020-01403-6. BMC Cardiovasc Disord. 2020. PMID: 32164560 Free PMC article.
The present meta-analysis evaluated the efficacy and safety of prasugrel- or ticagrelor-based TAPTs relative to that of clopidogrel TAPTs in patients with STEMI undergoing PCI. ...The pooled results with the fixed effects model indicated that after PCI patients in the p …
The present meta-analysis evaluated the efficacy and safety of prasugrel- or ticagrelor-based TAPTs relative to that of clopidogrel T …
Effect of ticagrelor versus prasugrel on platelet reactivity: a meta-analysis.
Zhang H, Zhang P, Dong P, Yang X, Wang Y, Zhang H, Yan J, Zhang Y, Zhang T, Li Y. Zhang H, et al. Coron Artery Dis. 2017 Nov;28(7):597-604. doi: 10.1097/MCA.0000000000000541. Coron Artery Dis. 2017. PMID: 28968313 Review.
For the loading dose, using the VerifyNow-P2Y12 (VN) test, the PR was similar for both the prasugrel and ticagrelor groups [MD=10.80 (-9.81-31.40), P=0.30]. Using the vasodilatorstimulated phosphoprotein test, the PR was also similar for both the ticagrelor and prasugre …
For the loading dose, using the VerifyNow-P2Y12 (VN) test, the PR was similar for both the prasugrel and ticagrelor groups [MD=10.80 …
Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
Fong LCW, Lee NHC, Yan AT, Ng MY. Fong LCW, et al. Cardiology. 2022;147(1):1-13. doi: 10.1159/000520673. Epub 2021 Nov 5. Cardiology. 2022. PMID: 34743081 Free PMC article.
INTRODUCTION: There have been inconsistent data on the direct comparison of prasugrel and ticagrelor. This meta-analysis was conducted to summarize the current available evidence. ...RESULTS: Of the 11 eligible RCTs with 6,098 patients randomized to prasugrel (n = 3 …
INTRODUCTION: There have been inconsistent data on the direct comparison of prasugrel and ticagrelor. This meta-analysis was conducte …
Prasugrel vs. Ticagrelor for Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.
Khan MS, Memon MM, Usman MS, Alnaimat S, Khan SU, Khan AR, Yamani N, Fugar S, Mookadam F, Krasuski RA, Doukky R. Khan MS, et al. Am J Cardiovasc Drugs. 2019 Oct;19(5):465-476. doi: 10.1007/s40256-019-00337-5. Am J Cardiovasc Drugs. 2019. PMID: 30828769
OBJECTIVE: We compared prasugrel and ticagrelor in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). ...CONCLUSIONS: The present analysis suggests that prasugrel might have a better efficacy profile than ticagrelor in p …
OBJECTIVE: We compared prasugrel and ticagrelor in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary inter …
549 results